Afatinib (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Afatinib" in Spanish language version.

refsWebsite

Global rank Spanish rank

4^th place

4^th place

1cancergrace.org

low place

low place

447^th place

668^th place

3,984^th place

low place

1medicines.org.uk

3,823^rd place

low place

1web.archive.org

1^st place

1^st place

68^th place

91^st place

1clinicaltrials.gov

5,225^th place

9,066^th place

1businesswire.com

615^th place

977^th place

2^nd place

2^nd place

719^th place

759^th place

businesswire.com

«Afatinib (BIBW 2992*) Triples Progression Free Survival in Phase III Study in Lung Cancer Patients | Business Wire». www.businesswire.com. Consultado el 11 de enero de 2016.

cancergrace.org

«Afatinib (BIBW-2992, Tomtovok) wins a battle (PFS) but loses the war (OS) for EGFR TKI-sensitive patients | GRACE :: Lung Cancer». cancergrace.org. Consultado el 29 de diciembre de 2015.

clinicaltrials.gov

«BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) - Full Text View - ClinicalTrials.gov». www.clinicaltrials.gov. Consultado el 11 de enero de 2016.

doi.org

dx.doi.org

Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC (2012). «Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial». The lancet oncology 13 (5): 528–38. PMID 22452896. doi:10.1016/S1470-2045(12)70087-6.

europa.eu

ema.europa.eu

«EMA». Archivado desde el original el 4 de febrero de 2014. Consultado el 11 de enero de 2016.

fda.gov

Research, Center for Drug Evaluation and. «Approved Drugs - Afatinib». www.fda.gov (en inglés). Consultado el 29 de diciembre de 2015.

medicines.org.uk

«Giotrif 20 mg/30 mg/40 mg/50 mg film-coated tablets - Summary of Product Characteristics (SPC) - (eMC)». www.medicines.org.uk. Consultado el 11 de enero de 2016.

medscape.com

reference.medscape.com

«Gilotrif (afatinib) dosing, indications, interactions, adverse effects, and more». reference.medscape.com. Consultado el 11 de enero de 2016.

nih.gov

ncbi.nlm.nih.gov

Minkovsky N, Berezov A. [Curr Opin Investig Drugs 9 (12): 1336–46 «BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors»]. Diciembre de 2008. PMID 19037840.
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC (2012). «Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial». The lancet oncology 13 (5): 528–38. PMID 22452896. doi:10.1016/S1470-2045(12)70087-6.
Yang, JC; Wu, YL; Schuler, M; Sebastian, M; Popat, S; Yamamoto, N; Zhou, C; Hu, CP; O'Byrne, K; Feng, J; Lu, S; Huang, Y; Geater, SL; Lee, KY; Tsai, CM; Gorbunova, V; Hirsh, V; Bennouna, J; Orlov, S; Mok, T; Boyer, M; Su, WC; Lee, KH; Kato, T; Massey, D; Shahidi, M; Zazulina, V; Sequist, LV (Febrero de 2015). «Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.». The Lancet. Oncology 16 (2): 141–51. PMID 25589191.

dailymed.nlm.nih.gov

«DailyMed - GILOTRIF- afatinib tablet, film coated». dailymed.nlm.nih.gov. Consultado el 11 de enero de 2016.

tga.gov.au

ebs.tga.gov.au

«TGA eBS - Product and Consumer Medicine Information Licence». www.ebs.tga.gov.au. Consultado el 11 de enero de 2016.

web.archive.org

«EMA». Archivado desde el original el 4 de febrero de 2014. Consultado el 11 de enero de 2016.